Associated tags: Health, Dietary supplement, Research, Mouse, Human, Bacteria, AAAS, Medicine, Obesity, Tissue
Locations: UNITED KINGDOM, UNITED STATES OF AMERICA, FRANCE, GERMANY, SPAIN, JAPAN
Retrieved on:
Tuesday, December 19, 2023
Dietary fiber,
Database,
Metagenomics,
Immune system,
Research,
Lipid metabolism,
Health,
Diabetes,
Blood,
HYA,
PCR,
Metabolomics,
Dicarboxylic acid,
Biomarker,
Feces,
Bacteria,
Antibiotics KYOTO, Japan, Dec. 19, 2023 /PRNewswire/ -- Japan's Noster Inc., a premier provider of gut microbiome analysis services, is proud to unveil groundbreaking updates in its research on cutting-edge gut bacteria-based metabolite and gut microbiota analysis services.
Key Points:
- KYOTO, Japan, Dec. 19, 2023 /PRNewswire/ -- Japan's Noster Inc., a premier provider of gut microbiome analysis services, is proud to unveil groundbreaking updates in its research on cutting-edge gut bacteria-based metabolite and gut microbiota analysis services.
- Noster's microbiome analysis approach simultaneously evaluates the composition of gut bacteria and its metabolite profile through a fusion of metagenomics and metabolomics.
- Metagenomics involves analyzing the genetic information of gut microbiota, while metabolomics addresses the properties of metabolites produced by the gut microbiome.
- By integrating these methodologies, Noster can assess both the function of the gut microbiome and the health status of the host.
Retrieved on:
Tuesday, December 19, 2023
Dietary fiber,
Database,
Metagenomics,
Immune system,
Research,
Lipid metabolism,
Health,
Diabetes,
Blood,
HYA,
PCR,
Metabolomics,
Dicarboxylic acid,
Biomarker,
Feces,
Bacteria,
Antibiotics KYOTO, Japan, Dec. 19, 2023 /PRNewswire/ -- Japan's Noster Inc., a premier provider of gut microbiome analysis services, is proud to unveil groundbreaking updates in its research on cutting-edge gut bacteria-based metabolite and gut microbiota analysis services.
Key Points:
- KYOTO, Japan, Dec. 19, 2023 /PRNewswire/ -- Japan's Noster Inc., a premier provider of gut microbiome analysis services, is proud to unveil groundbreaking updates in its research on cutting-edge gut bacteria-based metabolite and gut microbiota analysis services.
- Noster's microbiome analysis approach simultaneously evaluates the composition of gut bacteria and its metabolite profile through a fusion of metagenomics and metabolomics.
- Metagenomics involves analyzing the genetic information of gut microbiota, while metabolomics addresses the properties of metabolites produced by the gut microbiome.
- By integrating these methodologies, Noster can assess both the function of the gut microbiome and the health status of the host.
Retrieved on:
Monday, November 27, 2023
Research,
Scar,
Gene,
Cirrhosis,
Mouse,
Liver,
Liver disease,
HYA,
Non-alcoholic fatty liver disease,
Patient,
Pioglitazone,
Obesity,
Linoleic acid,
TGF,
Hepatic stellate cell,
Bacteria,
Death,
Shizuoka University,
Lactobacillus,
Scientific Reports,
Inflammation,
Fibrosis,
Dietary supplement,
Vaccine,
NAFLD Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
Key Points:
- Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
- A deeper analysis revealed that pioglitazone in fact increased the Lactobacillus species of bacteria in the gut, which in turn were generating the metabolites.
- Nonalcoholic fatty liver disease (NAFLD) and fibrosis: NAFLD is a chronic form of liver disease that affects 25% of the world's population—most likely people who do not consume much alcohol.
- A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF–β signaling in hepatic stellate cells.
Retrieved on:
Monday, November 27, 2023
Research,
Scar,
Gene,
Cirrhosis,
Mouse,
Liver,
Liver disease,
HYA,
Non-alcoholic fatty liver disease,
Patient,
Pioglitazone,
Obesity,
Linoleic acid,
TGF,
Hepatic stellate cell,
Bacteria,
Death,
Shizuoka University,
Lactobacillus,
Scientific Reports,
Inflammation,
Fibrosis,
Dietary supplement,
Vaccine,
NAFLD Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
Key Points:
- Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
- A deeper analysis revealed that pioglitazone in fact increased the Lactobacillus species of bacteria in the gut, which in turn were generating the metabolites.
- Nonalcoholic fatty liver disease (NAFLD) and fibrosis: NAFLD is a chronic form of liver disease that affects 25% of the world's population—most likely people who do not consume much alcohol.
- A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF–β signaling in hepatic stellate cells.
Retrieved on:
Thursday, October 26, 2023
Research,
Sport,
University of Newcastle,
Health,
Shosei-en Garden,
Max Planck Institute for Biology,
Max Planck Institute for Developmental Biology,
1916 American Grand Prize,
AAAS,
Chair,
University of Pennsylvania,
Drug development,
Fellow of the American Association for the Advancement of Science,
Disease,
Higashi Hongan-ji,
Partnership,
University,
Max Planck Society,
Managing editor,
Prize,
Pharmaceutical industry,
Physiology,
Science,
Medicine KYOTO, Japan, Oct. 26, 2023 /PRNewswire/ -- NOSTER Inc and Science, the prestigious academic journal, joined forces to host the NOSTER and Science Microbiome Prize Symposium and the 4th prize award ceremony on October 5th and 6th in Kyoto, Japan.
Key Points:
- KYOTO, Japan, Oct. 26, 2023 /PRNewswire/ -- NOSTER Inc and Science, the prestigious academic journal, joined forces to host the NOSTER and Science Microbiome Prize Symposium and the 4th prize award ceremony on October 5th and 6th in Kyoto, Japan.
- The NOSTER & Science Microbiome Prize rewards innovative research from young investigators studying how microbiota has the potential to contribute to our understanding of health and disease, or to guide novel therapeutic interventions.
- The Japanese company NOSTER established this award in 2020 in partnership with Science and its publisher, the American Association for the Advancement of Science (AAAS).
- NOSTER remains committed to supporting young scientists through this award and aims to contribute to breakthrough drug development driven by microbiome research.
Retrieved on:
Thursday, October 26, 2023
Research,
Sport,
University of Newcastle,
Health,
Shosei-en Garden,
Max Planck Institute for Biology,
Max Planck Institute for Developmental Biology,
1916 American Grand Prize,
AAAS,
Chair,
University of Pennsylvania,
Drug development,
Fellow of the American Association for the Advancement of Science,
Disease,
Higashi Hongan-ji,
Partnership,
University,
Max Planck Society,
Managing editor,
Prize,
Pharmaceutical industry,
Physiology,
Science,
Medicine KYOTO, Japan, Oct. 26, 2023 /PRNewswire/ -- NOSTER Inc and Science, the prestigious academic journal, joined forces to host the NOSTER and Science Microbiome Prize Symposium and the 4th prize award ceremony on October 5th and 6th in Kyoto, Japan.
Key Points:
- KYOTO, Japan, Oct. 26, 2023 /PRNewswire/ -- NOSTER Inc and Science, the prestigious academic journal, joined forces to host the NOSTER and Science Microbiome Prize Symposium and the 4th prize award ceremony on October 5th and 6th in Kyoto, Japan.
- The NOSTER & Science Microbiome Prize rewards innovative research from young investigators studying how microbiota has the potential to contribute to our understanding of health and disease, or to guide novel therapeutic interventions.
- The Japanese company NOSTER established this award in 2020 in partnership with Science and its publisher, the American Association for the Advancement of Science (AAAS).
- NOSTER remains committed to supporting young scientists through this award and aims to contribute to breakthrough drug development driven by microbiome research.
Tokyo University of Agriculture and Technology,
Extrapyramidal system,
Tissue,
University of Tokyo,
Cellulose,
Obesity,
Diet,
SCFA,
Diabetes,
Probiotic,
Digestion,
Fed,
Nutritional science,
Blood,
Metabolism,
Leuconostoc mesenteroides,
Kyoto University,
Yogurt,
Host,
HFD,
Mouse,
EPS,
Bacteria,
Health,
Bacillota,
System,
Prebiotic (nutrition),
Human,
Gum arabic,
Dietary supplement,
Leuconostoc,
Verrucomicrobiota,
Bacteroides,
Bacteroidota Probiotic foods such as miso and kimchi are rich in bacteria that keep the gut and body healthy.
Key Points:
- Probiotic foods such as miso and kimchi are rich in bacteria that keep the gut and body healthy.
- A complementary food group known as prebiotics (mainly fibrous foods) serve as fuel for these bacteria to thrive.
- Lactic acid bacteria, such as Leuconostoc mesenteroides (L. mesenteroides), are used in the fermentation process of fermented foods such as kimchi, sauerkraut, and pickles.
- The researchers thus focused their study on the potential role of LmEPS as a prebiotic fiber.
Tokyo University of Agriculture and Technology,
Extrapyramidal system,
Tissue,
University of Tokyo,
Cellulose,
Obesity,
Diet,
SCFA,
Diabetes,
Probiotic,
Digestion,
Fed,
Nutritional science,
Blood,
Metabolism,
Leuconostoc mesenteroides,
Kyoto University,
Yogurt,
Host,
HFD,
Mouse,
EPS,
Bacteria,
Health,
Bacillota,
System,
Prebiotic (nutrition),
Human,
Gum arabic,
Dietary supplement,
Leuconostoc,
Verrucomicrobiota,
Bacteroides,
Bacteroidota Probiotic foods such as miso and kimchi are rich in bacteria that keep the gut and body healthy.
Key Points:
- Probiotic foods such as miso and kimchi are rich in bacteria that keep the gut and body healthy.
- A complementary food group known as prebiotics (mainly fibrous foods) serve as fuel for these bacteria to thrive.
- Lactic acid bacteria, such as Leuconostoc mesenteroides (L. mesenteroides), are used in the fermentation process of fermented foods such as kimchi, sauerkraut, and pickles.
- The researchers thus focused their study on the potential role of LmEPS as a prebiotic fiber.
Water,
Degenerative disease,
AAA,
Aorta,
Ligand,
Heart,
Spleen,
Immune system,
Angiotensin,
Development,
Monocyte,
Aortic rupture,
Hypertension,
Cardiac arrest,
Bacteria,
NOD1,
Patient,
Abdominal aortic aneurysm,
Internal bleeding,
Research,
Injection,
Cardiovascular disease,
Incidence,
Kobe University,
Death,
Bone marrow,
AAAS,
Tissue,
Inflammation,
Rupture,
Stroke,
Swelling,
Risk,
Pharmaceutical industry,
Restaurant,
Vaccine,
Dietary supplement,
Mouse In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.
Key Points:
- In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.
- The composition of bacteria normally residing in the gut is known to play a role in other cardiovascular diseases.
- The suppression of gut bacteria was, thus, somehow leading to a reduced risk of AAA.
- This study revealed the link between gut bacteria and the onset of AAA.
Water,
Degenerative disease,
AAA,
Aorta,
Ligand,
Heart,
Spleen,
Immune system,
Angiotensin,
Development,
Monocyte,
Aortic rupture,
Hypertension,
Cardiac arrest,
Bacteria,
NOD1,
Patient,
Abdominal aortic aneurysm,
Internal bleeding,
Research,
Injection,
Cardiovascular disease,
Incidence,
Kobe University,
Death,
Bone marrow,
AAAS,
Tissue,
Inflammation,
Rupture,
Stroke,
Swelling,
Risk,
Pharmaceutical industry,
Restaurant,
Vaccine,
Dietary supplement,
Mouse In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.
Key Points:
- In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.
- The composition of bacteria normally residing in the gut is known to play a role in other cardiovascular diseases.
- The suppression of gut bacteria was, thus, somehow leading to a reduced risk of AAA.
- This study revealed the link between gut bacteria and the onset of AAA.
